Skip to main content
Erschienen in: Infection 1/2018

20.10.2017 | Original Paper

Suppressive antibiotic therapy with oral tetracyclines for prosthetic joint infections: a retrospective study of 78 patients

verfasst von: M. Pradier, O. Robineau, A. Boucher, M. Titecat, N. Blondiaux, M. Valette, C. Loïez, E. Beltrand, S. Nguyen, H. Dézeque, H. Migaud, Eric Senneville

Erschienen in: Infection | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This study aimed at describing the use of oral cyclines (i.e., doxycycline and minocycline) as suppressive antibiotic therapy (SAT) in patients with periprosthetic joint infections (PJIs).

Methods

Medical charts of all patients with surgical revisions for PJIs who were given cycline-based SAT because of a high failure of various origins were reviewed. Data regarding tolerability and effectiveness of cycline-based SAT were analysed.

Results

Seventy-eight patients of mean age 64 ± 17 years received cycline-base SAT in the period from January 2006 to January 2014. PJIs involved the knee in 37 patients (47%), the hip in 35 (45%), the elbow in 4 (5%), and the shoulder in 2 (3%) and were qualified as early in 31 patients (39.7%). Staphylococcus spp. were the most common pathogens accounting for 72.1% of the total number of bacterial strains identified. All included patients had surgery which consisted in debridement and implant retention in 59 of them (75.6%). Doxycycline and minocycline were prescribed as SAT in 72 (92%) and 6 (8%) patients, respectively. Adverse events were reported in 14 patients (18%), leading to SAT discontinuation in 6 of them (8%). After a mean follow-up of 1020 ± 597 days, a total of 22 (28.2%) patients had failed including 3 cases (3.8%) with documented acquisition of tetracycline resistance in initial pathogen(s).

Conclusions

Our results suggest that oral cyclines used as SAT in patients treated for PJI have an acceptable tolerability and effectiveness and appear to be a reasonable option in this setting.
Literatur
1.
Zurück zum Zitat Parvizi J, Gehrke T, Chen AF. Proceedings of the international consensus on periprosthetic joint infection. Bone Joint J. 2013;11:1450–2.CrossRef Parvizi J, Gehrke T, Chen AF. Proceedings of the international consensus on periprosthetic joint infection. Bone Joint J. 2013;11:1450–2.CrossRef
2.
Zurück zum Zitat Osmon DR, Berbari EF, Berendt AR, Lew D, Zimmerli W, Steckelberg JM, Rao N, Hanssen A, Wilson WR. Infectious Diseases Society of America. Infectious Diseases Society of America. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2013;56:25. doi:10.1093/cid/cis803.CrossRef Osmon DR, Berbari EF, Berendt AR, Lew D, Zimmerli W, Steckelberg JM, Rao N, Hanssen A, Wilson WR. Infectious Diseases Society of America. Infectious Diseases Society of America. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2013;56:25. doi:10.​1093/​cid/​cis803.CrossRef
3.
Zurück zum Zitat Saivin S, Houin G. Clinical pharmacokinetics of doxycycline and minocycline. Clin Pharmacokinet. 1988;15:355–66.CrossRefPubMed Saivin S, Houin G. Clinical pharmacokinetics of doxycycline and minocycline. Clin Pharmacokinet. 1988;15:355–66.CrossRefPubMed
4.
Zurück zum Zitat Gnarpe H, Dornbusch K, Hagg O. Doxycycline concentration levels in bone, soft tissue and serum after intravenous infusion of doxycycline. Scand J Infect Dis. 1976;1976:S54–7. Gnarpe H, Dornbusch K, Hagg O. Doxycycline concentration levels in bone, soft tissue and serum after intravenous infusion of doxycycline. Scand J Infect Dis. 1976;1976:S54–7.
5.
Zurück zum Zitat Agwuh KN, MacGowan A. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother. 2006;58:256–65.CrossRefPubMed Agwuh KN, MacGowan A. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother. 2006;58:256–65.CrossRefPubMed
7.
Zurück zum Zitat Bocker R, Muhlberg W, Platt D, Estler CJ. Serum level, half-life and apparent volume of distribution of doxycycline in geriatric patients. Eur J Clin Pharmacol. 1986;30:105–8.CrossRefPubMed Bocker R, Muhlberg W, Platt D, Estler CJ. Serum level, half-life and apparent volume of distribution of doxycycline in geriatric patients. Eur J Clin Pharmacol. 1986;30:105–8.CrossRefPubMed
8.
Zurück zum Zitat Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med. 2004;351:1645–54.CrossRefPubMed Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med. 2004;351:1645–54.CrossRefPubMed
9.
Zurück zum Zitat Byren I, Bejon P, Atkins BL, Angus B, Masters S, McLardy-Smith P, Gundle R, Berendt A. One hundred and twelve infected arthroplasties treated with ‘DAIR’ (debridement, antibiotics and implant retention): antibiotic duration and outcome. J Antimicrob Chemother. 2009;63:1264–71.CrossRefPubMedPubMedCentral Byren I, Bejon P, Atkins BL, Angus B, Masters S, McLardy-Smith P, Gundle R, Berendt A. One hundred and twelve infected arthroplasties treated with ‘DAIR’ (debridement, antibiotics and implant retention): antibiotic duration and outcome. J Antimicrob Chemother. 2009;63:1264–71.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Smith CJ, Sayles H, Mikuls TR, Michaud K. Minocycline and doxycycline therapy in community patients with rheumatoid arthritis: prescribing patterns, patient-level de determinants of use, and patient-reported side effects. Arthritis Res Therapy. 2011;13:R168.CrossRef Smith CJ, Sayles H, Mikuls TR, Michaud K. Minocycline and doxycycline therapy in community patients with rheumatoid arthritis: prescribing patterns, patient-level de determinants of use, and patient-reported side effects. Arthritis Res Therapy. 2011;13:R168.CrossRef
11.
Zurück zum Zitat Smith K, Leyden JJ. Safety of doxycycline and minocycline: a systematic review. Clin Ther. 2005;27:1329–42.CrossRefPubMed Smith K, Leyden JJ. Safety of doxycycline and minocycline: a systematic review. Clin Ther. 2005;27:1329–42.CrossRefPubMed
12.
Zurück zum Zitat Segreti J, Nelson JA, Trenholme GM. Prolonged suppressive antibiotic therapy for infected orthopedic prostheses. Clin Infect Dis. 1998;27:711–3.CrossRefPubMed Segreti J, Nelson JA, Trenholme GM. Prolonged suppressive antibiotic therapy for infected orthopedic prostheses. Clin Infect Dis. 1998;27:711–3.CrossRefPubMed
13.
Zurück zum Zitat Rao N, Crossett LS, Sinha RK, Le Frock JL. Long-term suppression of infection in total joint arthroplasty. Clin Orthop Relat Res. 2003;414:55–60.CrossRef Rao N, Crossett LS, Sinha RK, Le Frock JL. Long-term suppression of infection in total joint arthroplasty. Clin Orthop Relat Res. 2003;414:55–60.CrossRef
14.
Zurück zum Zitat Goulet JA, Pellicci PM, Brause BD, Salvati EM. Prolonged suppression of infection in total hip arthroplasty. J Arthroplast. 1988;3:109–16.CrossRef Goulet JA, Pellicci PM, Brause BD, Salvati EM. Prolonged suppression of infection in total hip arthroplasty. J Arthroplast. 1988;3:109–16.CrossRef
15.
Zurück zum Zitat Tsukayama DT, Wicklund B, Gustilo RB. Suppressive antibiotic therapy in chronic prosthetic joint infections. Orthopedics. 1991;14:841–4.PubMed Tsukayama DT, Wicklund B, Gustilo RB. Suppressive antibiotic therapy in chronic prosthetic joint infections. Orthopedics. 1991;14:841–4.PubMed
16.
Zurück zum Zitat Prendki V, Zeller V, Passeron D, Desplaces N, Mamoudy P, Stirnemann J, Marmor S, Ziza JM. Outcome of patients over 80 years of age on prolonged suppressive antibiotic therapy for at least 6 months for prosthetic joint infection. Int J Infect Dis. 2014;29:184–9.CrossRefPubMed Prendki V, Zeller V, Passeron D, Desplaces N, Mamoudy P, Stirnemann J, Marmor S, Ziza JM. Outcome of patients over 80 years of age on prolonged suppressive antibiotic therapy for at least 6 months for prosthetic joint infection. Int J Infect Dis. 2014;29:184–9.CrossRefPubMed
17.
Zurück zum Zitat Siqueira MB, Saleh A, Klika AK, O’Rourke C, Schmitt S, Higuera CA, Barsoum WK. Chronic suppression of periprosthetic joint infections with oral antibiotics increases infection-free survivorship. J Bone Joint Surg Am. 2015;97:1220–32.CrossRefPubMed Siqueira MB, Saleh A, Klika AK, O’Rourke C, Schmitt S, Higuera CA, Barsoum WK. Chronic suppression of periprosthetic joint infections with oral antibiotics increases infection-free survivorship. J Bone Joint Surg Am. 2015;97:1220–32.CrossRefPubMed
18.
Zurück zum Zitat Koeppe J, Johnson S, Morroni J, Siracusa-Rick C, Armon C. Suppressive antibiotic therapy for retained infected prosthetic joints: case series and review of the literature. Infect Dis Clin Pract. 2008;16:224–9.CrossRef Koeppe J, Johnson S, Morroni J, Siracusa-Rick C, Armon C. Suppressive antibiotic therapy for retained infected prosthetic joints: case series and review of the literature. Infect Dis Clin Pract. 2008;16:224–9.CrossRef
19.
Zurück zum Zitat Aboltins CA, Page MA, Buising KL, Jenney AW, Daffy JR, Choong PF, Stanley PA. Treatment of staphylococcal prosthetic joint infections with debridement, prosthesis retention and oral rifampicin and fusidic acid. Clin Microbiol Infect. 2007;13:586–91.CrossRefPubMed Aboltins CA, Page MA, Buising KL, Jenney AW, Daffy JR, Choong PF, Stanley PA. Treatment of staphylococcal prosthetic joint infections with debridement, prosthesis retention and oral rifampicin and fusidic acid. Clin Microbiol Infect. 2007;13:586–91.CrossRefPubMed
20.
Zurück zum Zitat Lora-Tamayo J, Murillo O, Iribarren JA, Soriano A, Sánchez-Somolinos M, Baraia-Etxaburu JM, Rico A, Palomino J, Rodríguez-Pardo D, Horcajada JP, Benito N, Bahamonde A, Granados A, del Toro MD, Cobo J, Riera M, Ramos A, Jover-Sáenz A, Ariza J, REIPI Group for the Study of Prosthetic Infection. A large multicenter study of methicillin-susceptible and methicillin-resistant Staphylococcus aureus prosthetic joint infections managed with implant retention. Clin Infect Dis. 2013;56:182–94.CrossRefPubMed Lora-Tamayo J, Murillo O, Iribarren JA, Soriano A, Sánchez-Somolinos M, Baraia-Etxaburu JM, Rico A, Palomino J, Rodríguez-Pardo D, Horcajada JP, Benito N, Bahamonde A, Granados A, del Toro MD, Cobo J, Riera M, Ramos A, Jover-Sáenz A, Ariza J, REIPI Group for the Study of Prosthetic Infection. A large multicenter study of methicillin-susceptible and methicillin-resistant Staphylococcus aureus prosthetic joint infections managed with implant retention. Clin Infect Dis. 2013;56:182–94.CrossRefPubMed
21.
Zurück zum Zitat Cobo J, Garcia San Miguel L, Euba G, Rodrıguez D, Garcıa-Lechuz JM, Riera M, Falgueras L, Palomino J, Benito N, del Toro MD, Pigrau C, Ariza J. Early prosthetic joint infection: outcomes with debridement and implant retention followed by antibiotic therapy. Clin Microbiol Infect. 2011;17:1632–7.CrossRefPubMed Cobo J, Garcia San Miguel L, Euba G, Rodrıguez D, Garcıa-Lechuz JM, Riera M, Falgueras L, Palomino J, Benito N, del Toro MD, Pigrau C, Ariza J. Early prosthetic joint infection: outcomes with debridement and implant retention followed by antibiotic therapy. Clin Microbiol Infect. 2011;17:1632–7.CrossRefPubMed
22.
Zurück zum Zitat Senneville E, Joulie D, Legout L, Valette M, Dezèque H, Beltrand E, Roselé B, d’Escrivan T, Loïez C, Caillaux M, Yazdanpanah Y, Maynou C, Migaud H. Outcome and predictors of treatment failure in total hip/knee prosthetic joint infections due to Staphylococcus aureus. Clin Infect Dis. 2011;53:334–40.CrossRefPubMedPubMedCentral Senneville E, Joulie D, Legout L, Valette M, Dezèque H, Beltrand E, Roselé B, d’Escrivan T, Loïez C, Caillaux M, Yazdanpanah Y, Maynou C, Migaud H. Outcome and predictors of treatment failure in total hip/knee prosthetic joint infections due to Staphylococcus aureus. Clin Infect Dis. 2011;53:334–40.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Betsch BY, Eggli S, Siebenrock KA, Täuber MG, Mühlemann K. Treatment of joint prosthesis infection in accordance with current recommendations improves outcome. Clin Infect Dis. 2008;46:1221–6.CrossRefPubMed Betsch BY, Eggli S, Siebenrock KA, Täuber MG, Mühlemann K. Treatment of joint prosthesis infection in accordance with current recommendations improves outcome. Clin Infect Dis. 2008;46:1221–6.CrossRefPubMed
24.
Zurück zum Zitat Fenske NA, Millns JL, Greer KE. Minocycline-induced pigmentation at sites of cutaneous inflammation. JAMA. 1980;244:1103–6.CrossRefPubMed Fenske NA, Millns JL, Greer KE. Minocycline-induced pigmentation at sites of cutaneous inflammation. JAMA. 1980;244:1103–6.CrossRefPubMed
25.
Zurück zum Zitat Lawrenson RA, Seaman HE, Sundström A, Williams TJ, Farmer RD. Liver damage associated with minocycline use in acne: a systematic review of the published literature and pharmaco-vigilance data. Drug Saf. 2000;23:333–49.CrossRefPubMed Lawrenson RA, Seaman HE, Sundström A, Williams TJ, Farmer RD. Liver damage associated with minocycline use in acne: a systematic review of the published literature and pharmaco-vigilance data. Drug Saf. 2000;23:333–49.CrossRefPubMed
26.
Zurück zum Zitat Lan J, Lahoti A, Lew DB. A severe case of minocycline-induced DRESS resulting in liver transplantation and autoimmune sequelae. Ann Allergy Asthma Immunol. 2016;116:367–8.CrossRefPubMed Lan J, Lahoti A, Lew DB. A severe case of minocycline-induced DRESS resulting in liver transplantation and autoimmune sequelae. Ann Allergy Asthma Immunol. 2016;116:367–8.CrossRefPubMed
27.
Zurück zum Zitat Meropol SB, Chan KA, Chen Z, Finkelstein JA, Hennessy S, Lautenbach E, Platt R, Schech SD, Shatin D, Metlay JP. Adverse events associated with prolonged antibiotic use. Pharmacoepidemiol Drug Saf. 2008;17:523–32.CrossRefPubMedPubMedCentral Meropol SB, Chan KA, Chen Z, Finkelstein JA, Hennessy S, Lautenbach E, Platt R, Schech SD, Shatin D, Metlay JP. Adverse events associated with prolonged antibiotic use. Pharmacoepidemiol Drug Saf. 2008;17:523–32.CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Dağ MS, Öztürk ZA, Akın I, Tutar E, Çıkman Ö, Gülşen MT. Drug-induced esophageal ulcers: case series and the review of the literature. Turk J Gastroenterol. 2014;25:180–4.CrossRefPubMed Dağ MS, Öztürk ZA, Akın I, Tutar E, Çıkman Ö, Gülşen MT. Drug-induced esophageal ulcers: case series and the review of the literature. Turk J Gastroenterol. 2014;25:180–4.CrossRefPubMed
29.
Zurück zum Zitat Hung YP, Lee JC, Lin HJ, Liu HC, Wu YH, Tsai PJ, Ko WC. Doxycycline and tigecycline: two friendly drugs with a low association with clostridium difficile infection. Antibiotics (Basel). 2015;4:216–22.CrossRefPubMedPubMedCentral Hung YP, Lee JC, Lin HJ, Liu HC, Wu YH, Tsai PJ, Ko WC. Doxycycline and tigecycline: two friendly drugs with a low association with clostridium difficile infection. Antibiotics (Basel). 2015;4:216–22.CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Doernberg SB, Winston LG, Deck DH, Chambers HF. Does doxycycline protect against development of Clostridium difficile infection? Clin Infect Dis. 2012;55:615–20.CrossRefPubMedPubMedCentral Doernberg SB, Winston LG, Deck DH, Chambers HF. Does doxycycline protect against development of Clostridium difficile infection? Clin Infect Dis. 2012;55:615–20.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Turner RB, Smith CB, Martello JL, Slain D. Role of doxycycline in Clostridium difficile infection acquisition. Ann Pharmacother. 2014;48:772–6.CrossRefPubMed Turner RB, Smith CB, Martello JL, Slain D. Role of doxycycline in Clostridium difficile infection acquisition. Ann Pharmacother. 2014;48:772–6.CrossRefPubMed
Metadaten
Titel
Suppressive antibiotic therapy with oral tetracyclines for prosthetic joint infections: a retrospective study of 78 patients
verfasst von
M. Pradier
O. Robineau
A. Boucher
M. Titecat
N. Blondiaux
M. Valette
C. Loïez
E. Beltrand
S. Nguyen
H. Dézeque
H. Migaud
Eric Senneville
Publikationsdatum
20.10.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Infection / Ausgabe 1/2018
Print ISSN: 0300-8126
Elektronische ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-017-1077-1

Weitere Artikel der Ausgabe 1/2018

Infection 1/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.